Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Pulmonary Hypertension: Diagnosis, Management, and Updates – Chairperson’s Perspective
Vallerie V. McLaughlin, MD
AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
Mazen Hanna, MD
Pulmonary Hypertension Management: Practice Trends and Updates
Victor Moles, MD
Ioana Preston, MD
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
Csaba P. Kovesdy, MD
Finnian R. Mc Causland, MD
FCS and SHTG: Are We Meeting the Need?
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Akshay S. Desai, MD
John McMurray, MD
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Ulrich Laufs, MD, PhD
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
Pasquale Perrone-Filardi, MD, PhD
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Julia Brandts, MD
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Managing a patient with residual risk: Applying recent evidence with EPA to practice
Prof. Kausik Ray
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
Prof. Alberto Zambon MD, PhD, FAHA
Azfar Zaman, MD
A novel CETP inhibitor to target CV risk reduction: Where could it fit in future lipid management?
Erin Michos
Innovating the clinical management of LDL-c: Exploring CETP as therapeutic target
John Kastelein, MD, PhD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
What are the challenges in making the right diagnosis in HCM?
Perry Elliott, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.